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tija-tives. We attempted to detrrmine whether changes in 
heart failure therapy since I989 have altered the prognostic 
significance of atrial fibrillation. 
Ebck~rn~~~L Atrial fihrlllation occurs in i.% to 3% of patients 
with heart failure. Despite the recognized potential for adterse 
e&cts, the impact of atrial tibrillation on prognosis is controver- 
sial. 
r\fefk&~. Two-year sunival for 750 consecutive patients dis- 
charged from a single hospital aIter evaluation for heart trans- 
plantation fmm 1985 to I989 (Group I, q = 359) and from 1990 to 
April 1993 (Croup II. n = 391) was analyzed in relation to atrial 
fibrillation. In Group I, class 1 antiarrhythmic drugs and hydral- 
azine vasodilator therapy were routinely allowed. In Group 11. 
amiodamne and angiotensin-convertinR enzyme inhibitors were 
tirst-line antiarrhythmic and vasodilating drubs. 
-. 
Atria1 fibrillation complicates the course of 15% to 30% (l-5) 
of patients with heart failure. It is associated with an increased 
risk of systemic cmboli and can contribute to hemodynamic 
deterioration due to rapid ventricular response and possibly 
loss of the atrial contribution to ventricular filling (S-11). 
Despite thcsc effects. its impact on survival in patients with 
heart failure has hecn controversial. In a previous study of 
patients with advanced heart failure, x (I) observed poorer 
survival and greater risk of sudden death during 1 year of 
follaw-up in patients with atrial fibrillation. In a large group of 
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Results. A bistoq of atrial librillation was pIWMt in 20% of 
patients in Cmup I and 24% of those in Group II. Patients with 
atrial fibrillation in the two groups had similar clinical and 
hemodynamic proliles. Among: patients with atrial fibrillation, 
those in Croup 11 bad a markedly better 2.year sunival (0.66 vs. 
0.39, p = 0.01) and sudden death-free survival (0.84 vs. 0.7& p = 
0.01) than those in Group I. In each time period. survival was 
worse for patients with than witbout atrial fibrillation in Group I 
(0.39 vs. 0.55, p = 0.002) but not in Group II (0.66 vs. 0.75, p = 
0.09). 
Concfusiotu. The prognosis of putients with advance4 bemt 
failure and atrial Rbrillation is improving. These findings support 
the practice of avoiding class I aatiarrbytbmic drugs in this group 
and may reflect recent beneficial changes in heart failure therapy. 
(J Am Cdl Ciwtiid 1996;28:1458-63) 
patients with less advanced heart failure (5), atrial fibrillation 
did not affect survival. The findings in smaller trials (12-14) 
have been mixed. None of these trials have controlled therapy 
of atrial fibrillation; the optimal approach remains to he 
defined. 
There is concern that class I antiarrhythmic drugs may 
increase mortality (B-17). Recent trials of smiodarone in 
survivors of myocardial infarction and in patients with heart 
failure (2.X18-21) suggest that :his drug does not increase 
mortality and is beneficial in some patient groups. In patients 
with advanced heart failure referred for possible heart trans- 
plantation, WC altered our approach to the management of 
arrhythmias in late 1989, withdrawing class 1 antiarrhythmic 
drugs when possible and using amiodarone as the first-line 
antiarrhythmic drug. In addition, angiotensinconverting en- 
zyme inhibitors became the preferred vasodilators. These 
,changes were followed by a substantial improvement in sur- 
vival during 1 year of follow-up study (22). The purpose of the 
present study was to determine whether the overall improve- 
ment in survival has been accompanied by a change in the 
impact of atrial fibrillation on survival during 2 years of 
follow-up study. 
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Methods 
From January of 1985 to April of lYY3. 754 consecutive 
patients with advanced. dilated heart failure and left ventricu- 
lar ejection fraction <0.40 were referred to the University of 
California. Los Angeles Cardiomyopathy Service. admitted to 
the hospital for optimization of medical therapy in conjunction 
with evaluation for heart transplantation and then discharged 
from the hospital. Of this group, we excluded 4 patients from 
this analysis because the history of previous atrial fibrillation 
was unclear, leaving a total study group of 750 patients. 
Methods of data acquisition and treatment have been previ- 
ously reported (22). Clinical and hemodynamic variables were 
prospectively collected at the time of hospital admission and 
entered into a data base. Patients were classified into two 
groups according to the date of initial hospital admission: 
Group I from 1985 tc 1983 (n = 339). Group !1 from 1090 to 
April 1993 (n = 391). 
Therapy. Medical management was directed by the same 
physicians throughout the time period studied and has been 
described in detail elsewhere (22.23). Briefly, right heart 
catheterization was performed. Intravenous sodium nitro- 
prusside and diuretic drugs were administered to approach 
hemodynamic goals of systemic vascular resistance <1,2W 
dynes-scm-s, pulmonary capillary wedge pressure 515 mm Hg 
and right atrial pressure 57 mm Hg while maintaining systolic 
blood pressure at ~80 mm Hg. Oral vasodilators and diuretic 
drugs were then substituted. Before 1989. the oral vasodilator 
was chosen arbitrarily by the attending cardiomyopathy team 
member or according to a randomized trial (24). In late 1990. 
after angiotensinconverting enzyme inhibitors were found to 
be superior to the hydralazinc and nitrate combination in the 
Vasodilators in Heart Failure Trial (V-H&T) and Hydral- 
azine vs Captopril (Hy-C) lrial (24.25). an angiotensin- 
converting enzyme inhibitor (usually captopril) was the initial 
oral vasodilator administered, in combination with isosoi bide 
dinitrate if tolerated. Hydralazine was added onlv if needed to 
achieve hemodynamic goals. Digoxin was administered at the 
discretion of the specific team physician. Anticoagulation was 
prescribed primarily for a history of atrial fibrillatiun, -previous 
embolic events or ‘mobile intracardiac thrombi observed on 
echocardiography (26). 
Arrhythmias. All patients were’evaluated by the arrhyth- 
mia consult service. Before 1989. patients who had atrial 
fibrillation or ventricular arrhythmias suppressed by class I 
antiarrhythmic drugs continued to receive these medications. 
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The approach to antiarrhythmic therapy was revised in late 
1YXY after some class I drugs were found to increase mortality 
in survivors of myocardial infarction (27). Class 1 drugs were 
then discontinued at the time of hospital admission’ unless 
administered for prophylaxis of sustained ventricu!ar tachycar- 
dia or ventricular fibrillation. Amiodaronc was recommended 
for atrial fibrillation or flutter and for frequent ventricular 
cc-topic beats on 24-h electrocardiogram (ECG) according to 
the following crileria: nonischemic cardiomyopathy with >4t) 
ventricular ectopic beats/h or two or more episodes of nonsus- 
tained ventricular tachycardia (>3 consecutive beats): previous 
infarction with >6 ventricular ectopic beats or any ventricular 
tachycardia. Contraindications to amiodarone were previous 
intolerance. first-degree or higher atrioventricular (AV) block 
(in the absence of a permanent pacemaker). bradycardia <6tl 
beats/min, hrpatic transaminase I~vcls exceeding twice normal 
and a pulmonary diffusing capacity or forced vital capacity 
<60% of predicted normal in patients accepted for future 
heart transplantation. Amiodarone was administered in doses 
of MM) mg daily for 2 weeks, then 4tMl mg daily for 2 weeks. then 
70 mg daily. Digoxin and warfarin doses were rcduccd by 50% 
when amiodarone therapy was initiated and then were moni- 
tored closely. For patients who continued to have atrial 
fibrillation after 4 to 6 weeks. cardiovcrsion was recommended. 
Follow-up. Patients were followed up by the Ahmanson- 
UCLA Cardiomyopathy Center in conjunction with their re- 
ferring physicians. Status was determined by telephone inter- 
view of the patient. family or physician in April 19Y5. at which 
time all surviving patients had been followed up for ~2 years. 
Thirty-five patients (4.6%) were lost to follow-up. Sudden 
death was defined as death occurring instantaneously, within 
15 min of a change in symptoms or unexpectedly during sleep. 
Statistics. Statistical analysis was performed with the use 
of BMDP programs (28). Continuous variables were compared 
by using analysis of variance with the Tukey method to assess 
individual differences. Proportions were evaluated by multiway 
chi-square tests with 2 X 2 tests performed to assess the source 
of intergroup differences. Two-year actuarial survival and 
sudden death-free survival were determined by using the 
Kaplan-Meier method and compared with the Mantel-Cox 
test. Patients who underwent heart transplantation were re- 
moved from survival analysis at the date of operation. 
To further adjust for possible baseline differences. a Cox 
proportional hazards model was constructed for total mor- 
tality. The variables assessed were histop .of atrial librilla- 
tion; atrial fibrillation at hospital discharge; age; gender: left 
ventricular ejection frdctkm , history of syncope: history of 
cardiac arrest; coronary artery disease; permanent pace- 
maker; implantable defibrillator: therapy with class I drugs. 
amiodarone, warfarin or angiotensin-converting enzyme in- 
hibitors; initial hospital evaluationafter 1989: serum sodium 
level: and admission and predischarge systolic blood pres- 
sure, pulmonary capillary wedge pressure. pulmonary artcry 
systolic pressure. right atrial pressure. and heart rat;; and 
predischarge cardiac index. Variables were entered into a 
stepwise model if their level of significance was ~0.1. The 
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Table 1. Clinical Characteristics 
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633 patients with complete data for all variables were 
included in the multivariate analyses. 
Results 
Of the 750 patients, 166 (22%; 20% of Group I and 24% of 
Group II) had a history of atrial fibrillation. The characteristics 
of patients with and without atrial fibrillation for Group I 
(1985-1989) and Group II (1990-April 1903) are shown in 
Table 1. Among the 166 patients with atrial fibrillation, the 
arrhythmia was persistent and present at hospital discharge in 
63% of those in Group I and 52% of those in Group II (p 1 
0.14). 
Group I versus Group II patients with atrial fibrillation. 
The changes in therapy over time are apparent in Table 2. 
From Group I to Group II, use of angiotensin-converting 
enzyme inhibitors, amiodarone, digoxin and warfarin in- 
creased, whereas use of class I antiarrhythmic drugs decreased. 
Group I and Group II patients with atria1 fibrillation had 
similar clinical and hemodynamic profiles (Table l), but their 
survival rates differed (Fig. 1). Among patients with atrial 
fibrillation those treated later (Group II) had a markedly 
better 2-year survival (mean -t SE 0.66 2 0.06) than that of 
patients in Group I (0.39 + 0.07, p = 0.001). They also had 
improved sudden death-free survival (0.84 2 0.05 vs. 0.70 Itr 
0.07, p = 0.01). These results were not altered by excluding 
from the analysis patients who underwent heart transplanta- 
tion and those who had an implantable defibrillator. 
Atrial fibrillation versus no atria1 llbrillatlon in eech time 
period. The better prognosis for patients with atrial fibrillation 
in Group II is further supported by comparison of the patients 
with and without atrial fibrillation in each time period. Within 
each group, patients with atrial fibrillation were older and 
more commonly had a history of syncope and a permanent 
pacemaker than did patients without atrial fibrillation. In 
Group 1, patients with and without atrial fibrillation had 
similar hemodynamic data (Table 1). However, in Group I, 
patients with- atrial fibrillation had worse survival (Fig. 2A) 
(absolute difference 0.16 [0.39 + 0.07 vs. 0.55 2 0.04, p = 
0.002]) and worse sudden death-free survival (absolute differ- 
ence 0.20 jO.70 2 0.07 vs. 0.90 2 0.02, p = 0.021) than that of 
patients without atria1 fibrillation. In Group II, patients with 
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Table 2. Therapy 
Group 1 (I985-19X9) 
/WI No Alih 
Group I1 (19!N-103) 
Atih No Atih p Valw 
No. of patients 
ACE inhibitor 
Dignrin 
Amkrfamnc 
Class 1 sntiarrhythmic drug 
Wsrfarin 
Nitrates 
ICD 
Pacemaker 
Data prrwntcd arc percenl c-f group, unless othunvis indicated. SCE = angiotcnsin+xmverting enzyme Atih = 
atria1 tihrillation: ICD = implantablc cardiovertcrdefihrillator. 
atria1 fibrillation had somewhat higher baseline and predis- 
charge cardiac filling pressures and a !ower cardiac index than 
did those without atrial fibrillation (Table I). However, despite 
their slightly worse hemodynamic profile. their survival (0.66 2 
0.06) was not statistically different from that of patients 
without atria1 fibrillation (0.75 2 0.03, p = 0.09). The absolute 
difference in total survival was 0.09. For sudden death-free 
survival, the absolute difference was only 0.06 (0.84 2 0.05 for 
patients with atrial fibril!ation vs. 0.90 2 0.02, p = 0.35). These 
results were not altered by excluding from the analysis patients 
who underwent heart transplantation and those who had an 
implantable defibrillator. 
Multivariate analysis. In the multivariable Cox propor- 
tional hazards model, evaluation after 1989, absence of an 
angiotensin-converting enzyme inhibitor, class I antiarrhyth- 
mic drug therapy, a history of syncope or previous cardiac 
arrest, permanent pacemaker, serum sodium, predischargc 
pulmonary artery systolic and pulmonary capillary wedge pres- 
sures and admission systolic arttirial biood pressure were 
associated with mortality. A history of atrial fibrillation (odds 
ratio [OR] 1.29,95% coniidence intervals [CI] 0.92 to 1.80) or 
Fire 1. Survival of patients with atrial fibrillation. Survival of Group 
I patients, initially evaluated between 1985 and 19b9, was significantly 
worse than that of Group II patients (1990 to April 1993), initially 
evaluated after 1990 (0.64 vs. 0.39, p = O.OKll). Dashed curves indicate 
standard errors. 
Survive! Atrial Fibrillation 
p=o.om 
atria1 fibrillation present at hospital discharge (OR 1.12, 95% 
CI 0.74 to 1.70) were not associated with increased mortali?. 
Discussion 
In a previous analysis that included 737 of the patients 
included in the present study, we (22) found a substantial 
Figure 2. Survival of patients with and without atrial fibrillation 
according to time of initial evaluation: Group I (1985 to 1989. panel A) 
and Group II (1990 to April 1993, panel B). Group I patients with 
atrial fibrillation had WLIIW survival than those withoul atrial fbrilla- 
tion (0.39 vs. 0%. p = 0.002). In Group II, the small difference in 
survival did not reach statistical signilicancc (u.66 vs. 0.75, p = 0.09). 
Dasbed EUIVCS indicate stanirrd erron. 
A 
Survival Group I 1985 1989 
‘FL 
a 
a.61 . 
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,improvement in l-year survival for patients with advanced 
heart failure referred for consideration ‘for heart transplanta- 
tion. ‘This improvement temporally coincided with ‘changes in 
medical therap:, increasing use of angiotcnsinconverting en- 
zyme inhibitors. amiodarone, digoxin. nitrates and warfarin 
and avoidance of class I antiarrhythmic drugs. The present 
analysis demonstrates a marked improvement in the prognosis 
of patients with advanced heart failure and atrial fibrillation. In 
an earlier analysis that included most of our Group I patients 
followed up for 1 year (1). atrial fibrillation was associated with 
worse survival and greater sudden death mortality. In the 
present analysis. extending follow-up to 2 years, atrial fibrilla- 
tion continued to portend worse outcome in Group I. After 
1989. however, atrial fibrillation no longer had a demonstrable 
adverse effect on survival. This change is unlikely to be a result 
of changes in patient characteristics over time for two reasons. 
First, the clinical and hemodynamic characteristics of patients 
with atria! fibrillation in Groups I and II were similar. Second. 
in Group II. survival of patients with and without atrial 
fibrillation was similar. From Group I to Group II tht 2-year 
survival rate of patients with atria! fibrillation improved from 
39% to 66% an absolute difference of 27% whereas that of 
patients without atrial fibrillation improved from 55% to 759& 
a difference of 20%. We cannot, however. exclude the possi- 
bility that atrial fibrillation still has a negative impact on 
survival that could not be demonstrated with the present 
sample size. Even after 1989 there is a trend for worse survival 
in the atrial fibrillation group and patients with atrial fihrilla- 
tion had a slightly worse hemodynamic prohle than that of 
patients without atrral fibrillation. 
It is tempting to speculate that the improvement in survival 
for patients with atrial fibrillation is related to changes in 
medical therapy. Furthermore, differences in therapy may have 
contributed to discrepancies in results of previous studies of 
atrial fibrillation in patients with heart failure (15). After 1989, 
use of amiodarone in the patier.ts with atrial fibrillation 
increased from 30% to 71% and use of class 1 antiarrhythmic 
drugs decreased from 33% to 10%. Amiodarone has been 
shown to be a safe drug in heart failure. In two recent 
randomized trials (2,3), amiodaronc therapy improved survival 
in one and had no impact, either adverse or beneficial, in the 
other. In contrast, that class I antiarrhythmic drugs may he 
detrimental is supported by studies in survivors of myocardial 
infarction and post hoc analysis of a recent atrial fibrillation 
trial (15-17.27). Because of its depressant effect on the AV 
node. amiodarone may help control the ventricular response to 
atrial fibrillation, even if it fails to restore sinus rhythm. 
Persistent, rapid ventricular rates are detrimental, depressing 
ventricular function as well as reducing the time for ventricular 
filling (8.9,29-31). Warfarin use also increased after 1989. 
Although heart failure is associated with an increased risk of 
thrombocmholi in atrial fibrillation, we doubt that’ increasing 
warfarin use was a major factor in improving survival (6). 
Recent analyses of a subgroup of our patients on the transplant 
waiting list (26) and the V-HeFT trial found an annual 
incidence’ of systemic embJli of ~3% in patients with atrial 
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fibrillation, 30% to 76% of whom were receiving anticoagulant 
therapy (26,32). Greater use of angiotensin-converting enzyme 
inhibitors and digoxin may also have contributed to better 
survival. 
Limitations of the study. We cannct. determine which 
therapy or combination of therapeutic strategies is responsible 
for the improvement in survival. This was not a randomized 
trial. and therapy was individualized. Although there is a trend 
for more patients with atrial fibrillation in Group II to have 
sinus rhythm at hospital discharge, we cannot determine 
whether restoration of sinus rhythm was associated with better 
survival. When amiodarone therapy was initiated for atria1 
fibrillation we recommended electrical cardioversion 4 to 6 
weeks after hospital discharge if atrial fibrillation persisted to 
that time. However, the decision to perform cardioversion was 
often left to the referring physician. Ambulatory ECGs were 
not routinely obtained during follow-up to assess persistence of 
sinus rhythm. 
Clinical implications. The optimal management of atrial 
fibrillation in heart failure has not been adequately defined. On 
the basis of current data. some recommendations appear 
reasonable. Class I antiarrhythmic drugs should be avoided. 
Amiodarone can he used to attempt to maintain sinus rhythm, 
hut whether this approach is better than adequate rate control 
is unknown. Amiodarone may also be useful for controlling a 
rapid ventricular response in some patients. However, with 
current heart failure management, including the use of 
angiotensin-converting enzyme inhibitors, the prognosis of 
patients with atrial fibrillation and advanced heart failure is 
improving. 
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